Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending ...

During a tumultuous 13-month tenure at the FDA, Makary pursued a wide range of ambitious initiatives. Going forward, their status under the next commissioner is unclear.

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious ...

Dr. Marty Makary's resignation from his post atop the Food and Drug Administration is widening a leadership gap that already ...

Alleging a "pattern of deception" in studies done more than a decade ago, the U.S. government proposed a ban on federal ...

Marty Makary is resigning as President Donald Trump's Food and Drug Administration head. The surgeon and health researcher's ...

The biotech company has a pre-clinical program with the U.S. Army and a vaccine center at a Korean university. An American citizen on Sunday takes photos on his phone after he was evacuated from the ...